{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:45Z","timestamp":1790739465781,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"La Ligue R\u00e9gionale Grand Ouest contre le Cancer","award":["CD16, CD22, CD44, CD49, CD72, CD79 and CD85"],"award-info":[{"award-number":["CD16, CD22, CD44, CD49, CD72, CD79 and CD85"]}]},{"name":"association ARSMESO44","award":["meso44"],"award-info":[{"award-number":["meso44"]}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC","doi-asserted-by":"crossref","award":["PJA 20191209661"],"award-info":[{"award-number":["PJA 20191209661"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-16-CE18-0016"],"award-info":[{"award-number":["ANR-16-CE18-0016"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale pour la Recherche, France","doi-asserted-by":"crossref","award":["LabEX IGO, ANR-11-LABX-0016-01"],"award-info":[{"award-number":["LabEX IGO, ANR-11-LABX-0016-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00262-023-03486-4","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:02:23Z","timestamp":1689768143000},"page":"3309-3322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells"],"prefix":"10.1007","volume":"72","author":[{"given":"Marion","family":"Grard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Idjellidaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atousa","family":"Arbabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Berland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Combredet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soizic","family":"Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Dehame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Labarri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Fradin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boisgerault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Tangy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Fonteneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"3486_CR1","doi-asserted-by":"crossref","unstructured":"Macedo N, Miller DM, Haq R, Kaufman HL (2020) Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 8","DOI":"10.1136\/jitc-2020-001486"},{"key":"3486_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","volume":"31","author":"C Achard","year":"2018","unstructured":"Achard C, Surendran A, Wedge ME et al (2018) Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 31:17\u201324","journal-title":"EBioMedicine"},{"key":"3486_CR3","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","volume":"68","author":"A Gauvrit","year":"2008","unstructured":"Gauvrit A, Brandler S, Sapede-Peroz C et al (2008) Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 68:4882\u20134892","journal-title":"Cancer Res"},{"key":"3486_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-12-2733","volume":"19","author":"JB Guillerme","year":"2013","unstructured":"Guillerme JB, Boisgerault N, Roulois D et al (2013) Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 19:1147\u20131158","journal-title":"Clin Cancer Res"},{"key":"3486_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135\u2013146","journal-title":"Nat Rev Cancer"},{"key":"3486_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107889","volume":"98","author":"X Meng","year":"2021","unstructured":"Meng X, Sun X, Liu Z, He Y (2021) A novel era of cancer\/testis antigen in cancer immunotherapy. Int Immunopharmacol 98:107889","journal-title":"Int Immunopharmacol"},{"key":"3486_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","volume":"95","author":"S Gnjatic","year":"2006","unstructured":"Gnjatic S, Nishikawa H, Jungbluth AA et al (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1\u201330","journal-title":"Adv Cancer Res"},{"key":"3486_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1084\/jem.187.2.265","volume":"187","author":"E Jager","year":"1998","unstructured":"Jager E, Chen YT, Drijfhout JW et al (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265\u2013270","journal-title":"J Exp Med"},{"key":"3486_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cr.2016.155","volume":"27","author":"RF Wang","year":"2017","unstructured":"Wang RF, Wang HY (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 27:11\u201337","journal-title":"Cell Res"},{"key":"3486_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, Al-Khadairi G, Roelands J et al (2018) NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 9:947","journal-title":"Front Immunol"},{"key":"3486_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2174\/1566523217666170102110502","volume":"16","author":"F Allagui","year":"2017","unstructured":"Allagui F, Achard C, Panterne C et al (2017) Modulation of the type I interferon response defines the sensitivity of human melanoma cells to oncolytic measles virus. Curr Gene Ther 16:419\u2013428. https:\/\/doi.org\/10.2174\/1566523217666170102110502","journal-title":"Curr Gene Ther"},{"key":"3486_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/387362","volume":"2013","author":"N Boisgerault","year":"2013","unstructured":"Boisgerault N, Guillerme JB, Pouliquen D et al (2013) Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. Biomed Res Int 2013:387362","journal-title":"Biomed Res Int"},{"key":"3486_CR13","doi-asserted-by":"publisher","first-page":"44892","DOI":"10.18632\/oncotarget.6285","volume":"6","author":"C Achard","year":"2015","unstructured":"Achard C, Boisgerault N, Delaunay T et al (2015) Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Oncotarget 6:44892\u201344904. https:\/\/doi.org\/10.18632\/oncotarget.6285","journal-title":"Oncotarget"},{"key":"3486_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jtho.2019.12.128","volume":"15","author":"T Delaunay","year":"2020","unstructured":"Delaunay T, Achard C, Boisgerault N et al (2020) Frequent homozygous deletions of type i interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus. J Thoracic Oncol\u202f: Official Public Int Assoc Study of Lung Cancer 15:827\u2013842. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.128","journal-title":"J Thoracic Oncol : Official Public Int Assoc Study of Lung Cancer"},{"key":"3486_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1568009617666170222125035","volume":"18","author":"P Msaouel","year":"2018","unstructured":"Msaouel P, Opyrchal M, Dispenzieri A et al (2018) Clinical trials with oncolytic measles virus: current status and future prospects. Curr Cancer Drug Targets 18:177\u2013187","journal-title":"Curr Cancer Drug Targets"},{"key":"3486_CR16","doi-asserted-by":"crossref","unstructured":"Backhaus PS, Veinalde R, Hartmann L, et al (2019) Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 Agonists. Viruses 11","DOI":"10.3390\/v11100914"},{"key":"3486_CR17","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-17-2651","volume":"24","author":"T Speck","year":"2018","unstructured":"Speck T, Heidbuechel JPW, Veinalde R et al (2018) Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin Cancer Res 24:2128\u20132137","journal-title":"Clin Cancer Res"},{"key":"3486_CR18","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/leu.2017.120","volume":"31","author":"A Dispenzieri","year":"2017","unstructured":"Dispenzieri A, Tong C, LaPlant B et al (2017) Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31:2791\u20132798","journal-title":"Leukemia"},{"key":"3486_CR19","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1038\/s41467-021-26506-2","volume":"12","author":"PN Frantz","year":"2021","unstructured":"Frantz PN, Barinov A, Ruffie C et al (2021) A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. Nat Commun 12:6277","journal-title":"Nat Commun"},{"key":"3486_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","volume":"15","author":"K Ramsauer","year":"2015","unstructured":"Ramsauer K, Schwameis M, Firbas C et al (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15:519\u2013527","journal-title":"Lancet Infect Dis"},{"key":"3486_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/mt.2013.249","volume":"22","author":"JG Pol","year":"2014","unstructured":"Pol JG, Zhang L, Bridle BW et al (2014) Maraba virus as a potent oncolytic vaccine vector. Mol Ther 22:420\u2013429. https:\/\/doi.org\/10.1038\/mt.2013.249","journal-title":"Mol Ther"},{"key":"3486_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/v12020242","volume":"12","author":"E Busch","year":"2020","unstructured":"Busch E, Kubon KD, Mayer JKM et al (2020) Measles vaccines designed for enhanced CD8+ T cell activation. Viruses 12:242. https:\/\/doi.org\/10.3390\/v12020242","journal-title":"Viruses"},{"key":"3486_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0022-1759(01)00477-X","volume":"258","author":"JF Fonteneau","year":"2001","unstructured":"Fonteneau JF, Larsson M, Somersan S et al (2001) Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 258:111\u2013126","journal-title":"J Immunol Methods"},{"key":"3486_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1183\/09031936.00160210","volume":"38","author":"D Roulois","year":"2011","unstructured":"Roulois D, Vignard V, Gueugnon F et al (2011) Recognition of pleural mesothelioma by mucin-1(950\u2013958)\/human leukocyte antigen A*0201-specific CD8+ T-cells. Eur Respir J 38:1117\u20131126","journal-title":"Eur Respir J"},{"key":"3486_CR25","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/1521-4141(200107)31:7<2007::aid-immu2007>3.0.co;2-s","volume":"31","author":"H Benlalam","year":"2001","unstructured":"Benlalam H, Labarri\u00e8re N, Linard B et al (2001) Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur J Immunol 31:2007\u20132015. https:\/\/doi.org\/10.1002\/1521-4141(200107)31:7%3c2007::aid-immu2007%3e3.0.co;2-s","journal-title":"Eur J Immunol"},{"key":"3486_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3109\/14653249.2012.689129","volume":"14","author":"D Coulais","year":"2012","unstructured":"Coulais D, Panterne C, Fonteneau JF, Gregoire M (2012) Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads. Cytotherapy 14:887\u2013896","journal-title":"Cytotherapy"},{"key":"3486_CR27","doi-asserted-by":"publisher","first-page":"11546","DOI":"10.1128\/JVI.77.21.11546-11554.2003","volume":"77","author":"C Combredet","year":"2003","unstructured":"Combredet C, Labrousse V, Mollet L et al (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77:11546\u201311554","journal-title":"J Virol"},{"key":"3486_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682","journal-title":"Nat Methods"},{"key":"3486_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin SA, Benes V, Garson JA et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611\u2013622. https:\/\/doi.org\/10.1373\/clinchem.2008.112797","journal-title":"Clin Chem"},{"key":"3486_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2006.07.006","volume":"123","author":"K Ohgimoto","year":"2007","unstructured":"Ohgimoto K, Ohgimoto S, Ihara T et al (2007) Difference in production of infectious wild-type measles and vaccine viruses in monocyte-derived dendritic cells. Virus Res 123:1\u20138. https:\/\/doi.org\/10.1016\/j.virusres.2006.07.006","journal-title":"Virus Res"},{"key":"3486_CR31","doi-asserted-by":"crossref","unstructured":"Sanchez David RY, Combredet C, Sismeiro O et al (2016) Comparative analysis of viral RNA signatures on different RIG-I-like receptors. eLife 5: 11275","DOI":"10.7554\/eLife.11275"},{"key":"3486_CR32","doi-asserted-by":"publisher","first-page":"e00643","DOI":"10.1128\/JVI.00643-17","volume":"91","author":"M Mura","year":"2017","unstructured":"Mura M, Combredet C, Najburg V et al (2017) Nonencapsidated 5\u2032 copy-back defective interfering genomes produced by recombinant measles viruses are recognized by RIG-I and LGP2 but not MDA5. J Virol 91:e00643-e717. https:\/\/doi.org\/10.1128\/JVI.00643-17","journal-title":"J Virol"},{"key":"3486_CR33","doi-asserted-by":"crossref","unstructured":"Donnelly OG, Errington-Mais F, Steele L et al (2011) Measles virus causes immunogenic cell death in human melanoma. Gene Ther","DOI":"10.1038\/gt.2011.205"},{"key":"3486_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4049\/jimmunol.1402664","volume":"196","author":"JF Fonteneau","year":"2016","unstructured":"Fonteneau JF, Brilot F, Munz C, Gannage M (2016) The tumor antigen NY-ESO-1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer. J Immunol 196:64\u201371","journal-title":"J Immunol"},{"key":"3486_CR35","doi-asserted-by":"publisher","first-page":"e1407897","DOI":"10.1080\/2162402x.2017.1407897","volume":"7","author":"T Delaunay","year":"2018","unstructured":"Delaunay T, Violland M, Boisgerault N et al (2018) Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology 7:e1407897. https:\/\/doi.org\/10.1080\/2162402x.2017.1407897","journal-title":"Oncoimmunology"},{"key":"3486_CR36","first-page":"11","volume":"7","author":"EF Velazquez","year":"2007","unstructured":"Velazquez EF, Jungbluth AA, Yancovitz M et al (2007) Expression of the cancer\/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)\u2013correlation with prognostic factors. Cancer Immun 7:11","journal-title":"Cancer Immun"},{"key":"3486_CR37","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","volume":"12","author":"C Barrow","year":"2006","unstructured":"Barrow C, Browning J, MacGregor D et al (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764\u2013771","journal-title":"Clin Cancer Res"},{"key":"3486_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1006\/jsre.2001.6148","volume":"98","author":"JS Goydos","year":"2001","unstructured":"Goydos JS, Patel M, Shih W (2001) NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 98:76\u201380","journal-title":"J Surg Res"},{"key":"3486_CR39","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder NN, Wallen H, Cao J et al (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698\u20132703","journal-title":"N Engl J Med"},{"key":"3486_CR40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TL et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21:1019\u20131027","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03486-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:04:02Z","timestamp":1694167442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03486-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3486"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03486-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FT and JFF are authors of patents on MV. FT owns equity in Oncovita, an oncolytic virotherapy company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}